
POV: Pharmacist
“Nulla feugiat ipsum arcu mi penatibus fringilla cursus ut mi. At eget condimentum pellentesque in amet.”
The Pharmacist's View >
Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.Intro text here.
The Pharmacist's View >
The Nurse's View >
April 29, 2025
The PRESTIGE-AF trial evaluated whether direct oral anticoagulants (DOACs) could prevent ischemic stroke without significantly increasing the risk of...
April 29, 2025
This consensus statement puts forth a call to action to establish a protocol for Code ICH, similar to current strategies used for the management of...
April 29, 2025
This study evaluated the effectiveness of andexanet alfa compared to usual care in patients with acute intracerebral hemorrhage who had recently...
April 29, 2025
A multicenter, retrospective, observational study of 1133 patients with apixaban or rivaroxaban-related ICrH who received andexanet or PCCs showing...
April 29, 2025
This study highlights the importance of rapid treatment in improving survival and discharge to hospice for patients with anticoagulation-associated...
April 29, 2025
This publication discusses the timing of anticoagulation resumption in patients with mechanical heart valves following intracerebral hemorrhage...
April 25, 2025
Should the dose of apixaban be reduced in the very elderly who do not meet two of the three dose reduction criteria (Age >80yo, SCr >1.5, <60kg WT)?
April 25, 2025
Are DOACs safe to use in those with low body weight (60 kg)? Should doses be reduced outside of package insert recommendations?
April 25, 2025
ACE Rapid Resource summary from the AC Forum outlining management strategies for the treatment of patients w/ Cancer-Associated VTE based on landmark...
Clinical FAQs provide practical guidance for healthcare professionals through offering evidence-based answers to common questions. These FAQs cover a wide range of topics to help healthcare professionals deliver high-quality patient care.
Are DOACs safe to use in those with low body weight (60 kg)? Should doses be reduced outside of package insert recommendations?
Read MoreIn patients prescribed warfarin for mechanical heart valve replacement (MHV), does an INR that is below the therapeutic range warrant LMWH therapy...
Read MoreShould a patient with a history of recurrent VTE be bridged with LMWH?
Read MoreJoining the AC Forum is quick, easy, and free—simply complete our online registration form, and you'll instantly access all membership benefits, including newsletters and webinar invitations. By becoming a member, you join a community of excellence dedicated to improving patient care and advancing the management of thromboembolic diseases. Take the next step in your professional journey and register now to start enjoying the benefits of membership today.
"The knowledge I gained from AC Forum has been invaluable in tackling complex patient cases. While I had a solid foundation, the resources and insights provided by AC Forum helped me expand my expertise significantly."
"The AC Forum Resource Center is a goldmine of information. The resources are incredibly helpful and directly applicable to my daily practice. I frequently turn to the AC Forum website for guidance and support."
"The AC Forum webinars offer invaluable insights into treatment options and the decision-making process behind them. Each patient is unique, and weighing the benefits and risks can be challenging. "